Should Pharma have Unrestricted Access to Doctors’ Prescribing Profiles?

Kenneth Lin

First published 4/25/11 on the American Family Physician Community Blog

For many years, it has been a common practice for pharmaceutical companies to use individual physicians’ prescribing profiles to tailor their marketing and sales strategies. For example, if a drug rep had access to data showing that a particular family doctor was prescribing more of a competitor’s anti-hypertensive drug, he or she might make a point of dropping off a batch of samples to change that doctor’s prescribing practices. As explained in a previous AFP Journal Club, this strategy is often very effective for the drug company, but ends up increasing patients’ out-of-pocket expenses in the long run.

Continue reading “Should Pharma have Unrestricted Access to Doctors’ Prescribing Profiles?”